Mie Azuma

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Masahiro Kobayashi, Masatoshi Kudo, Namiki Izumi et al. · Journal of Gastroenterology · 2019 · 83 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +13

Economic Burden of Alzheimer’s Disease Dementia in Japan

Shunya Ikeda, Masaru Mimura, Manabu Ikeda et al. · Journal of Alzheimer s Disease · 2021 · 42 citations · Full text

Medicine, Geriatric Medicine, Neurology +17

Impact of the Severity of Alzheimer’s Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan

Takumi Ashizawa, Ataru Igarashi, Yukinori Sakata et al. · Journal of Alzheimer s Disease · 2021 · 28 citations · Full text

Medicine, Geriatric Medicine, Dementia +16

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

Ataru Igarashi, Mie Azuma, Quanwu Zhang et al. · Neurology and Therapy · 2023 · 20 citations · Full text

Pharmacy, Geriatric Medicine, Pharmacoeconomics +17

Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial

Shunya Ikeda, Masatoshi Kudo, Namiki Izumi et al. · Value in Health Regional Issues · 2021 · 15 citations

Pharmacy, Oncology, Pharmacoeconomics +17